Literature DB >> 9850917

Neuropathology of Alzheimer's disease: a critical update.

K A Jellinger1, C Bancher.   

Abstract

The unequivocal diagnosis of Alzheimer's disease (AD) rests on histopathological evidence at brain autopsy or biopsy. The morphology of AD includes cerebral atrophy, deposition of beta A4 amyloid (A beta) (senile plaques and amyloid angiopathy), neuritic changes (neuritic plaques, neurofibrillary tangles (NFT) and neuropil threads) with formation of paired helical filaments (PHF) containing polymerized hyperphosphorylated tau protein triplet, causing disruption of the neuronal cytoskeleton with loss of synapses and neurons, with altered cortico-cortical connectivity, leading to disconnection of the cerebral cortex. Defining criteria for the morphologic diagnosis of AD is difficult due to the phenotypic heterogeneity of the disease, the absence of specific markers, and overlap of AD morphology with that observed in non-demented elderly individuals. This gray zone between normal to pathologic aging and full-fledged AD represents an important diagnostic problem and should be overcome by better standardized criteria that will allow to minimize interrater and interlaboratory variability in the diagnosis of AD. Current criteria for the morphologic diagnosis of AD are based on (semi)quantitative assessment of diffuse and neuritic plaques (NIA), exclusively neuritic plaques (CERAD), plaques and NFT in neocortex and hippocampus (Tierney et al., 1988), and staging of hierarchic spreading of neuritic AD changes (Braak and Braak, 1991); all of them have weaknesses and need to be revalidated. Multivariant analysis of an autopsy series of elderly subjects revealed significant correlations between psychostatus and both the CERAD criteria and Braak staging. Recent recommendations of the NIA-Reagan Institute for the morphologic diagnosis of AD are presented. Although the role of plaques and NFT in the pathogenesis of AD remains undetermined, clinicopathological correlative studies have shown that both lesions, if present in sufficient numbers, particularly in the neocortex, are considered the best morphological signposts for AD. Recent studies on neuron death in AD that, at least in part, appears different from classical apoptosis and may precede the symptomatic stage of AD, have shown varying results indicating only indirect relationship between DNA fragmentation and both A beta deposition and NFTs. Both these AD-typical markers appear to increase the risk of cells to degenerate, but are not the sole responsibles of the degenerative process in AD, the basic mechanisms of which remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850917     DOI: 10.1007/978-3-7091-7508-8_8

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  44 in total

1.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

2.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 3.  The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease.

Authors:  Gholamreza Azizi; Shadi S Navabi; Ahmed Al-Shukaili; Mir H Seyedzadeh; Reza Yazdani; Abbas Mirshafiey
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24

Review 4.  The A, B, C's of factitious disorder: a response to Turner.

Authors:  James C Hamilton; Marc D Feldman; Jeffrey W Janata
Journal:  Medscape J Med       Date:  2009-01-27

Review 5.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

6.  Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective?

Authors:  Xinyi Li; Eliezer Masliah; Natàlia Reixach; Joel N Buxbaum
Journal:  J Neurosci       Date:  2011-08-31       Impact factor: 6.167

7.  Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport.

Authors:  Brian W Kunkle; Badri N Vardarajan; Adam C Naj; Patrice L Whitehead; Sophie Rolati; Susan Slifer; Regina M Carney; Michael L Cuccaro; Jeffery M Vance; John R Gilbert; Li-San Wang; Lindsay A Farrer; Christiane Reitz; Jonathan L Haines; Gary W Beecham; Eden R Martin; Gerard D Schellenberg; Richard P Mayeux; Margaret A Pericak-Vance
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

Review 8.  Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B.

Authors:  Keith A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

9.  Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Authors:  Leslie Crews; Brian Spencer; Paula Desplats; Christina Patrick; Amy Paulino; Edward Rockenstein; Lawrence Hansen; Anthony Adame; Douglas Galasko; Eliezer Masliah
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

10.  Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss.

Authors:  G William Rebeck; Hyang-Sook Hoe; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.